halcion
pfizer new zealand limited - triazolam 0.25mg - tablet - 0.25 mg - active: triazolam 0.25mg excipient: brilliant blue fcf colloidal silicon dioxide dioctyl sodium sulfosuccinate 85% + sodium benzoate 15% lactose monohydrate magnesium stearate maize starch microcrystalline cellulose
trycam
douglas pharmaceuticals limited - triazolam 0.125mg - tablet - 0.12 mg - active: triazolam 0.125mg excipient: erythrosine indigo carmine lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate
trycam
douglas pharmaceuticals limited - triazolam 0.25mg - tablet - 0.25 mg - active: triazolam 0.25mg excipient: erythrosine indigo carmine lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate
halcion
pfizer australia pty ltd - triazolam -
voriconazole accord
accord healthcare s.l.u. - voriconazole - aspergillosis; candidiasis; mycoses - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole accord should be administered primarily to patients with progressive, possibly life-threatening infections.
trimexol 0.25 mg
trima israel pharmaceutical products maabarot ltd - pramipexole dihydrochloride monohydrate 0.25 mg - tablets - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa. for symptomatic treatment of moderate to severe idiopathic restless legs syndrome.
trimexol 1
trima israel pharmaceutical products maabarot ltd - pramipexole dihydrochloride monohydrate 1 mg - tablets - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with lovodopa.
triregol coat. tabl.
gedeon richter plc - levonorgestrel 50 µg (pink tablet); ethinylestradiol 30 µg (pink tablet); levonorgestrel 75 µg (white tablet); ethinylestradiol 40 µg (white tablet); levonorgestrel 125 µg (ochre tablet); ethinylestradiol 30 µg (ochre tablet) - coated tablet - ethinylestradiol 30 µg; levonorgestrel 50 µg; levonorgestrel 75 µg; ethinylestradiol 40 µg; levonorgestrel 125 µg; ethinylestradiol 30 µg - levonorgestrel and ethinylestradiol
triazol 2.5 mg film-coated tablet
oncolife corporation; distributor: accord healthcare limited - philippine branch office - letrozole - film-coated tablet - 2.5 mg
voriconazole actavis 200 milligram film coated tablet
actavis group ptc ehf - voriconazole - film coated tablet - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp